Evidence-based therapy of primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 6, 1999, Pages 607-615

  Heathcote, E Jenny ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Drug therapy; Outcome measures; Primary biliary cirrhosis (PBC); Randomized controlled trials; Therapeutic trials

Indexed keywords

AZATHIOPRINE; BILE ACID; BISPHOSPHONIC ACID DERIVATIVE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; URSODEOXYCHOLIC ACID;

BILE DUCT; BONE MARROW SUPPRESSION; CHOLESTASIS; CLINICAL TRIAL; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GRANULOMATOUS INFLAMMATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; META ANALYSIS; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0032772919     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199906000-00005     Document Type: Review

References (57)

1. 1• Mahl T, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20:707-713. The tremendous difference in survival between asymptomatic and symptomatic patients suggests that clinical trials should stratify for this factor.
2. 2 Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49:556-559.
3. 3 Tadrous PJ, Goldin RD. How many portal tracts are necessary to make a diagnosis of significant bile duct loss (SBDL)? [Abstract]. J Pathol 1997; 181:11A.
4. 4 Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976; 70:656-659.
5. 5• Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89:1084-1091. Well-conducted study but rather high withdrawal rate; it is unfortunate that baseline conditions were not the same for the two randomized groups.
6. 6 Routhier G, Janossy G, Epstein O, Thomas HC, Sherlock S. Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet 1980; ii:1223-1226.
7. 7 Minuk G, Bohme C, Burgess E, Hershfield N, Kelly J, Shaffer E, et al. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 1988; 95:1356-1363.
8. 8 Robson S, Neuberger J, Keller HP, Abisch E, Neiderberger W, von Graffenried B, et al. Pharmacokinetic study of cyclosporine A (Sandimmun®) in patients with primary biliary cirrhosis. Br J Clin Pharmacol 1984; 18:627-631.
9. 9•• Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20:137-140. A classic article assessing the value of serum bilirubin as a surrogate marker of survival.
10. 10 Wiesner RH, Ludwig J, Lindor K, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322:1419-1424.
11. 11 Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308:1-7.
12. 12 Colina F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 1992; 102:1319-1324.
13. 13•• Lombard M, Portmann B, Neuberger J. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104:519-526. Superbly designed and conducted study but dissimilarity in baseline characteristics between the two randomized groups necessitated complex statistical analyses which reduces the credibility of the results.
14. 14 Howat HT, Ralston AJ, Varley H, Wilson JA. The late results of long-term treatment of primary biliary cirrhosis by corticosteroids. Rev Int Hepatol 1966; 16:227-238.
15. 15 Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OFW. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992; 15:336-344.
16. 16• Wolfhagen FHJ, van Buren HR, denOuden JW, Hop WCJ, van Leeuwen JPTM, Schalm SW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26:325-330. Well-conducted study clearly shows the benefit of bisphosphonate therapy in reducing vertebral bone loss in PBC patients treated with steroids.
17. 17 Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991; 101:1332-1338.
18. 18 Hendrickse M, Rigney E, Giaffer MH, Soomoro I, Triger DR, Underwood JC, et al. Low-dose methotrexate in primary biliary cirrhosis: long-term results of a placebo-controlled trial [Abstract]. Hepatology 1997; 26:248A.
19. 19 Lindor KD, Dickson ER, Jorgenson RA, Anderson ML, Wiesner RH, Gores GJ, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995; 22:1158-1162.
20. 20• Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigam MI, Pappas SC, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91:1327-1334.
21. 21 Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315:1448-1454.
22. 22 Warnes TW, Smith A, Lee F, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. Hepatology 1987; 5:1-7.
23. 23 Bodenheimer H, Schaffner F, Pessullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95:124-129.
24. 24 Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30:642-649.
25. 25• Poupon R, Poupon RE, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; i:834-836. The pivotal pilot study of UDCA in PBC demonstrating a marked benefit of therapy on serum bilirubin.
26. 26 Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97:1268-1274.
27. 27 Hadziyannis SJ, Hadziyannis ES, Makris A. A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) [Abstract]. Hepatology 1989; 10:580.
28. 28 Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, et al. A multi-centre double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990; 25:774-780.
29. 29•• Poupon RE, Balkau B, Eschwege E, Poupon R, the UDCA-PBC Study Group. A multicentre controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324:1548-1554. Landmark paper on the value of UDCA in the management of PBC.
30. 30 Hwang SJ, Chan C, Lee S-D, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the long term treatment of primary biliary cirrhosis: a short term, randomized, double-blind controlled, cross-over study with long term follow-up. J Gastroenterol Hepatol 1993; 8:217-223.
31. 31 Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicentre trial. J Hepatology 1993; 17:332-338.
32. 32• Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-1290. A four-year study validating the earlier results reported by Poupon et al. [29]
33. 33• Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicentre double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149-1156. A well-conducted study with a simple primary outcome measure - bilirubin, which also confirmed the beneficial effect of UDCA in PBC.
34. 34 Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW. A two year controlled trial examining the effectiveness of UDCA in PBC. J Gastroenterol Hepatol 1994; 9:162-168.
35. 35• Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-766. Another well-conducted study using a smaller dose of UDCA than the previous three large UDCA trials - with less clinical benefit.
36. 36 Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Ryden BO, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multi-centre, double-blind, randomized controlled study. Scand J Gastroenterol 1997; 32:179-186.
37. 37• Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, LaRosa T, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 1997; 26:9-21. Excellent study of scanning electron microscopy showing the toxic effects of unconjugated bile acids on the biliary epithelial cells.
38. 38•• Jazrawi RP, Caestecker JS, Goggin PM, Britten AJ, Joseph AEA, Maxwell JD, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106:134-143. Excellent study using an in vivo technique to measure bile acid transport in PBC and primary sclerosing cholangitis (PSC).
39. 39 Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15:677-684.
40. 40•• Setchell KDR, Rodrigues CMP, Clerici C, Solinas A, Morelli A, Gartung C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997; 112:226-235. A landmark paper on the effect of UDCA in man, which actually measured the cytoplasmic and nuclear concentrations of endogenous bile salts in hepatocytes.
41. 41• Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98:424-428.
42. 42 Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12:492-497.
43. 43 Alpini G, Glaser S, Caligiuri A, Phinizy J, Rodgers R, Francis H, et al. Ursodeoxycholic acid feeding inhibits secretin-induced cholangiocyte secretory processes in bile duct ligated rats [Abstract]. Gastroenterology 1998; 114:A1202.
44. 44 Calmus Y, Guechot J, Podevin P, Bonnetis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-α production by monocytes. Hepatology 1992; 16:719-723.
45. 45 Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16:358-364.
46. 46 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15.
47. 47 Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39:475-478.
48. 48• Poupon RE, Poupon R, Balkau B, the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330:1342-1347. The first time UDCA is shown to improve survival in patients with PBC - this effect was not seen after only two years of therapy [29].
49. 49•• Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890. This study combined the raw data from the three largest UDCA trials and this had sufficient power to determine a survival benefit to UDCA-treated patients using the intention-to-treat principle and despite many patients going on open-label UDCA after two years on placebo.
50. 50 Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J Gastroenterol Hepatol 1992; 7:277-282.
51. 51 Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, et al. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J Hepatol 1996; 24:88-94.
52. 52 Poupon RE, Huet PM, Poupon R, Bonnand A-M, Van Nhieu JT, Zafrani ES, et al. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996; 4:1098-1103.
53. 53 Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner L. Ursodeoxycholic acid and prenisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996; 25:49-57.
54. 54 Wolfhagen FH, van Buren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth J Med 1994; 44:84-90.
55. 55• Lindor KD, Dickson ER, Jorgenson RA, Anderson ML, Wiesner RH, Gores GJ, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995; 22:1158-1162. A greater than 10% withdrawal rate due to methotrexate (moderate dose) toxicity is of great concern.
56. 56 Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997; 27:143-149.
57. 57 Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol 1993; 18:9-14.